Publications

As leaders in the field of epigenetics, we continue to contribute to the scientific understanding of this important therapeutic space by sharing our findings in peer reviewed publications in leading life science academic journals. We also share our data with the scientific community at global conferences in the form of posters and oral presentations. Highlighted below are some of our recent publications and key articles that continue to build upon the progress of science in this field.

RVX PUBLICATIONS

2019 Publication in Clinical Epigenetics
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.

2019 Publication in American Journal of Respiratory and Critical Care Medicine
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.

2018 Publication in Atherosclerosis
Apabetalone Downregulates Factors and Pathways Associated with Vascular Calcification.

2018 Publication in American Journal of Cardiovascular Drugs
The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

2018 Publication in Kidney & Blood Pressure Research
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.

2018 Publication in Kidney International Reports
Benefit of Apabetalone on Plasma Proteins in Renal Disease. Supplemental Materials Available Here.

2017 Publication in American Journal of Cardiovascular Drugs
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.

2017 Publication in Molecular Pharmacology
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.

2017 Publication in Journal of Cardiovascular Translational Research
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).

2016 Publication in Atherosclerosis
RVX-208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL and Represses Pathways that Contribute to Cardiovascular Disease.

2016 Publication in Data in Brief
Data on Gene and Protein Expression Changes Induced by Apabetalone (RVX-208) in ex vivo Treated Human Whole Blood and Primary Hepatocytes.

2016 Publication in Metabolism
Effects of the BET-inhibitor, RVX-208 on the HDL Lipidome and Glucose Metabolism in Individuals with Prediabetes: A Randomized Controlled Trial.

2015 Publication in Expert Opinion on Investigational Drugs
An Evaluation of RVX-208 for the Treatment of Atherosclerosis.

2015 Publication in European Biopharmaceutical Review
New Direction.

2014 Publication in Atherosclerosis
A Novel BET Bromodomain Inhibitor, RVX-208, Shows Reduction of Atherosclerosis in Hyperlipidemic ApoE Deficient Mice.

2013 Publication in PLoS One
RVX-208, an Inducer of ApoA-I in Humans, is a BET Bromodomain Antagonist.

2012 Publication in Cardiovascular Drugs and Therapy
ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

2011 Publication in Journal of the American College of Cardiology
Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease

RVX POSTERS

2019 Alzheimer's Association International Conference (AAIC) Effects of the Epigenetic BET-Inhibitor Small Molecule Apabetalone on Cognition in Patients with Diabetes and Cardiovascular Disease.

2019 56th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress 2019 Apabetalone, a Selective Bromodomain and Extra-Terminal (BET) Inhibitor, Reduces Serum FGF23 in Cardiovascular Disease and Chronic Kidney Disease Patients.

2019 American Diabetes Association's 79th Scientific Sessions (ADA 2019) Apabetalone (RVX-208) Attenuates an Inflammatory Milieu that Enhances Adhesion of Monocytes to Endothelial Cells in Type 2 Diabetes Mellitus with Cardiovascular Diasease Patients.

2019 87th European Atherosclerosis Society (EAS) Congress Apabetalone (RVX-208) Attenuates Inflammatory Milieu Underlying Adhesion of Monocytes to Endothelial Cells in Type 2 Diabetes Mellitus with Cardiovascular Disease Patients. 

2019 Vascular Discovery: From Genes to Medicine
Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in Vitro and in CVD Patients.

2019 Vascular Discovery: From Genes to Medicine
Apabetalone (RVX-208) Inhibits Key Pro-Atherogenic Mediators and Pathways in Diabetes and Inflammatory Conditions; in Vitro and in Patients.

2019 14th​ International Conference on Alzheimer's and Parkinson's Diseases
Epigenetic Inhibitor Apabetalone Downregulates Brain Endothelial and Microglial Cell Activation that Contributes To Neurodegenerative Disease.

2019 American College of Cardiology’s Scientific Session
BET Protein Inhibition and Cognition: A Pre-Specified Substudy of the BETonMACE Phase 3 Trial Evaluating Apabetalone in Patients With Diabetes and Acute Coronary Syndrome.

2019 American College of Cardiology’s Scientific Session
Apabetalone, an Epigenetic BET Inhibitor in a Phase 3 Trial, Inhibits Vascular Inflammation and Cellular Adhesion Leading to Beneficial Outcomes in CVD Patients.

2018 AHA Scientific Sessions
Apabetalone (RVX-208) Suppresses Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and LPS-Challenged Mouse Liver and Monocyte Adhesiveness to Activated Endothelial Cells.

2018 AHA Scientific Sessions
Cardiovascular Evaluation of the Selective Bet Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study.

2018 American Society of Nephrology (ASN) Kidney Week
Apabetalone Downregulates Factors and Pathways Associated with Vascular Calcification.

2018 Clinical Trials on Alzheimer's Disease Conference (CTAD - Barcelona)
Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia and Vascular Endothelial Cells that Contribute to Neurodegenerative Disease.

2018 Clinical Trials on Alzheimer's Disease Conference (CTAD - Shanghai)
Effect of the BET Protein Inhibitor Apabetalone on Serum Markers of Potential Importance for Cognitive Decline in Cardiovascular Disease Patients.

2018 Alzheimer's Association International Conference (AAIC)
Apabetalone (An Epigenetic BET-Inhibitor Small Molecule): A Substudy Evaluating Effects on Cognition in Diabetes Patients with Cardiovascular Disease.

2018 European Renal Association European Dialysis and Transplant Association (ERA-EDTA) Congress
BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60. 

2018 European Renal Association European Dialysis and Transplant Association (ERA-EDTA) Congress
Inhibition of BET Proteins with Apabetalone Reduces Mediators of Vascular Calcification In Vitro and in CKD Patients. 

2017 American Diabetes Association Scientific Sessions
Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity. 

2017 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress
Effects of Apabetalone (RVX-208) on Serum Albumin in Subjects with CVD, Diabetes and Chronic Kidney Disease; a Post-Hoc Analysis of the ASSURE and SUSTAIN Clinical Trials. 

2017 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress
Apabetalone, A Bromodomain and Extraterminal Protein Inhibitor, Decreases Key Factors in Vascular Calcification in Vitro and in Clinical Trials. 

2017 International Conference on Alzheimer's & Parkinson's Diseases
Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia that Contribute to Neurodegenerative Disease.

2017 Atherosclerosis, Thrombosis & Vascular Biology Scientific Sessions
Apabetalone (RVX-208), a Selective CET Protein Inhibitor, Reduces Expression of Acute Phase Response Markers in Vitro and In Patients with Cardiovascular Disease and Chronic Kidney Disease.

2016 American Society of Nephrology Conference
Apabetalone Reduces Levels of Key Markers Involved in Vascular Calcification. 

2016 American Heart Association Scientific Sessions
Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in Vitro and in Patients with Cardiovascular Disease.

2016 European Society of Cardiology Congress
Modulation of the Complement Cascade in Cardiovascular Disease Patients by a Bromodomain and Extraterminal (BET) Protein Inhibitor. 

2016 Atherosclerosis, Thrombosis & Vascular Biology Scientific Sessions
Apabetalone (RVX-208) has Anti-Atherosclerotic, Anti-Thrombotic and Anti-Inflammatory Effects in Patients with Cardiovascular Disease. 

2015 American Heart Association Scientific Sessions
RVX-208, a Selective Bromodomain Extra-Terminal (BET) Protein Inhibitor, Acts on Several Pathways to Benefit Cardiovascular Risk. 

2015 American Society of Nephrology Conference
Alkaline Phosphatase Lowering by Selective BET Inhibition, a Novel Mechanism for MACE Reduction in High Risk CVD, Diabetes and CKD Patients; a Post-hoc Analysis of Phase 2b Studies with Apabetalone (RVX-208).

2015 American Society of Nephrology Conference
Apabetalone (RVX-208), a First-in-Class Epigenetic BET Inhibitor, has Effects on ALP and eGFR in Subjects with CVD and CKD; a Post-hoc Analysis of ASSERT, SUSTAIN and ASSURE Clinical Trials.